Gestational diabetes & diabetes in pregnancy
Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes: Outcomes of a Population-Based Real-World Study
Authors' conclusion
CGM use in pregnancy is associated with improved glycemia. The treatment effect of CGM in this real-world study is similar to that observed in the CONCEPTT study, thus supporting CGM use in pregnant women with T1D.
Study context
- Population
- Pregnant women with T1D across Australian centers, 2015–2025
- Participants
- 951 women
- Exposure
- Continuous glucose monitoring (CGM) users vs nonusers
- CGM usersn = 456
- Outcome
- Change in HbA1c from first to third trimester
- Follow-up
- First to third trimester
Methodological detailsmulticentre
- Multicentre
Main finding
Change in HbA1c over pregnancy
Adjusted mean difference
−0.20 %
95% CI −0.40 to 0.00
P = 0.037
Between CGM users and Nonusers
adjusted mean difference −0.20 % (95% CI −0.40 to 0.00); P = 0.037
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
First-trimester HbA1c as predictor of HbA1c change
- First-trimester HbA1c was the strongest predictor of HbA1c change
- P < 0.001
LGA or SGA offspring; mean birthweight
- CGM use not associated with large- or small-for-gestational-age offspring
- No significant difference between the groups in mean birthweight
- Adjusted for first-trimester HbA1c, first-trimester BMI, insulin regimen, parity and year of delivery
Cesarean section, primiparous women
- CGM use associated with lower odds of cesarean section
- aOR 0.22 (95% CI 0.08-0.58)
- P
- P = 0.002
- Adjusted for confounders
Original publication
Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes: Outcomes of a Population-Based Real-World Study. Diabetes Technol Ther. Published 1 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →